Well one thing that is changing is the potential approval of Vicineum. The milestone payments and royalties will add a lot of cash. Enzon will get 0.75% of all sales of Vicineum. The potential worldwide annual sales could be as high as $3 billion once approved in US, Europe, China, etc. Assuming approval, ENZN would get $3.5 million milestone payments for each country it’s approved in along with a potential of up to $20+ million in royalty payments. This could be huge for ENZN.
We will find out on Monday the estimated date of FDA approval along with if it qualifies for fast track.
Yes, I know they do have the preferreds. However, that gives Enzon a total of about $48 million in cash now that they can use to acquire a company to use ENZN as a “Public company acquisition vehicle”
Also another positive is the comments from both the outgoing and incoming CEO’s that they made toward the bottom of the last PR.
If/when Vicineum is approved, I think ENZN could be a multi dollar stock. You should check out Vicineum when you have time. It’s looking like it has potential to treat other conditions besides bladder cancer. If that’s the case, we could be sitting on a gold mine here IMO
News 
Market Data 
Discover 
